Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04)

Simple item page
dc.contributor.authorColeman, R. E.
dc.contributor.authorCollinson, M.
dc.contributor.authorGregory, W.
dc.contributor.authorMarshall, H.
dc.contributor.authorBell, R.
dc.contributor.authorDodwell, D.
dc.contributor.authorKeane, M.
dc.contributor.authorGil, M.
dc.contributor.authorBarrett-Lee, P.
dc.contributor.authorRitchie, D.
dc.contributor.authorBowman, A.
dc.contributor.authorLiversedge, V.
dc.contributor.authorDe Boer, R. H.
dc.contributor.authorPassos-Coelho, J. L.
dc.contributor.authorO'Reilly, S.
dc.contributor.authorBertelli, G.
dc.contributor.authorJoffe, J.
dc.contributor.authorBrown, J. E.
dc.contributor.authorWilson, C.
dc.contributor.authorTercero, J. C.
dc.contributor.authorJean-Mairet, J.
dc.contributor.authorGomis, R.
dc.contributor.authorCameron, D.
dc.contributor.funderUniversity of Sheffielden
dc.contributor.funderNovartisen
dc.contributor.funderBayeren
dc.contributor.funderAmgenen
dc.contributor.funderJanssen Biotechen
dc.contributor.funderCologneen
dc.contributor.funderInbiomotionen
dc.date.accessioned2019-09-09T16:11:49Z
dc.date.available2019-09-09T16:11:49Z
dc.date.issued2018-09-27
dc.description.abstractAdjuvant bisphosphonates improve disease outcomes in postmenopausal early breast cancer (EBC) but the long-term effects are poorly described. The AZURE trial (ISRCTN79831382) was designed to determine whether adjuvant zoledronic acid (ZOL) improves disease outcomes in EBC. Previous analyses showed no effect on overall outcomes but identified benefits in postmenopausal women. Here we present the long-term risks and benefits of adjuvant ZOL with 10-years follow-up. Patients and methods 3360 patients with stage II/III breast cancer were included in an academic, international, phase III, randomized, open label trial. Patients were followed up on a regular schedule until 10 years. Patients were randomized on a 1:1 basis to standard adjuvant systemic therapy +/− intravenous ZOL 4 mg every 3–4 weeks x6, and then at reduced frequency to complete 5 years treatment. The primary outcome was disease free survival (DFS). Secondary outcomes included invasive DFS (IDFS), overall survival (OS), sites of recurrence, skeletal morbidity and treatment outcomes according to primary tumor amplification of the transcription factor, MAF. Pre-planned subgroup analyses focused on interactions between menopausal status and treatment effects. Results With a median follow up of 117 months [IQR 70.4–120.4), DFS and IDFS were similar in both arms (HRDFS = 0.94, 95%CI = 0.84–1.06, p = 0.340; HRIDFS = 0.91, 95%CI = 0.82–1.02, p = 0.116). However, outcomes remain improved with ZOL in postmenopausal women (HRDFS = 0.82, 95%CI = 0.67–1.00; HRIDFS = 0.78, 95%CI = 0.64–0.94). In the 79% of tested women with a MAF FISH negative tumor, ZOL improved IDFS (HRIDFS = 0.75, 95%CI = 0.58–0.97) and OS HROS = 0.69, 95%CI = 0.50–0.94), irrespective of menopause. ZOL did not improve disease outcomes in MAF FISH + tumors. Bone metastases as a first DFS recurrence (BDFS) were reduced with ZOL (HRB-DFS = 0.76, 95%CI = 0.63–0.92, p = 0.005). ZOL reduced skeletal morbidity with fewer fractures and skeletal events after disease recurrence. 30 cases of osteonecrosis of the jaw in the ZOL arm (1.8%) have occurred. Conclusions Disease benefits with adjuvant ZOL in postmenopausal early breast cancer persist at 10 years of follow-up. The biomarker MAF identified a patient subgroup that derived benefit from ZOL irrespective of menopausal status.en
dc.description.statusPeer revieweden
dc.description.versionPublished Versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.citationColeman, R.E., Collinson, M., Gregory, W., Marshall, H., Bell, R., Dodwell, D., Keane, M., Gil, M., Barrett-Lee, P., Ritchie, D. and Bowman, A., 2018. Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04). Journal of bone oncology, 13,(12pp). DOI:10.1016/j.jbo.2018.09.008en
dc.identifier.doi10.1016/j.jbo.2018.09.008en
dc.identifier.endpage135en
dc.identifier.issn2212-1374
dc.identifier.journaltitleJournal of Bone Oncologyen
dc.identifier.startpage123en
dc.identifier.urihttps://hdl.handle.net/10468/8491
dc.identifier.volume13en
dc.language.isoenen
dc.publisherElsevier GmbHen
dc.relation.urihttp://www.sciencedirect.com/science/article/pii/S2212137418302628
dc.rights© 2018 The Authors. Published by Elsevier GmbHen
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/en
dc.subjectZoledronic aciden
dc.subjectBreast canceren
dc.subjectAZUREen
dc.subjectAdjuvant treatmenten
dc.titleBenefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04)en
dc.typeArticle (peer-reviewed)en
Files
Original bundle
Now showing 1 - 3 of 3
Thumbnail Image
Name:
1-s2.0-S2212137418302628-main.pdf
Size:
2.59 MB
Format:
Adobe Portable Document Format
Description:
Published version
Download
Thumbnail Image
Name:
1-s2.0-S2212137418302628-mmc1.zip
Size:
348 B
Format:
http://www.iana.org/assignments/media-types/application/zip
Description:
Published version
Download
Thumbnail Image
Name:
1-s2.0-S2212137418302628-mmc2.pdf
Size:
440.34 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medicine - Journal Articles